SEC Form 4Coverage since Jun 17, 2026
$PVLA insider trading
Over the last 12 months, Palvella Therapeutics insiders reported no purchases and 2 sales totaling $1.1M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1.1M 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $PVLA · 12Mvia TradingView
Top insiders · 12m
Goin KathleenChief Operating Officer2× · $1.1M
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $149.28 | $642K | -100% | plan · 4 tranches |
| Jun 17, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $110.73 | $476K | -100% | plan · 3 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PVLA feed.